Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

The purpose of this study is to determine the toxicity and efficacy of temozolomide (TMZ) p.o. followed by subcutaneous (s.c.) low-dose interleukin-2 (IL2), granulocyte–monocyte colony stimulating factor (GM-CSF) and interferon-α 2b (IFNα) in patients with metastatic melanoma. A total of 74 evaluabl...

Descripción completa

Detalles Bibliográficos
Autores principales: de Gast, G C, Batchelor, D, Kersten, M J, Vyth-Dreese, F A, Sein, J, van de Kasteele, W F, Nooijen, W J, Nieweg, O E, Waal, M A de, Boogerd, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377058/
https://www.ncbi.nlm.nih.gov/pubmed/12610499
http://dx.doi.org/10.1038/sj.bjc.6600717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377058/
https://www.ncbi.nlm.nih.gov/pubmed/12610499
http://dx.doi.org/10.1038/sj.bjc.6600717

Ejemplares similares